pulmonary embolism thrombolysis studyclinicaltrialresults.org/slides/acc...

27
Pulmonary Embolism Thrombolysis Study an investigator-initiated, investigator-sponsored trial The PEITH Investigators ClinicalTrials.gov # NCT00639743 EudraCT # 2006-005328-18

Upload: trancong

Post on 06-Mar-2018

221 views

Category:

Documents


1 download

TRANSCRIPT

Page 1: Pulmonary Embolism Thrombolysis Studyclinicaltrialresults.org/Slides/ACC 2013/Konstantinides_PEITHO_ACC... · Pulmonary Embolism Thrombolysis Study an investigator-initiated, investigator-sponsored

Pulmonary Embolism Thrombolysis Study an investigator-initiated, investigator-sponsored trial

The PEITH Investigators

ClinicalTrials.gov # NCT00639743 EudraCT # 2006-005328-18

Page 2: Pulmonary Embolism Thrombolysis Studyclinicaltrialresults.org/Slides/ACC 2013/Konstantinides_PEITHO_ACC... · Pulmonary Embolism Thrombolysis Study an investigator-initiated, investigator-sponsored

Rationale: risk-adjusted treatment of acute PE

Thrombolysis?

Page 3: Pulmonary Embolism Thrombolysis Studyclinicaltrialresults.org/Slides/ACC 2013/Konstantinides_PEITHO_ACC... · Pulmonary Embolism Thrombolysis Study an investigator-initiated, investigator-sponsored

Primary To investigate the clinical benefits (efficacy) of thrombolysis with tenecteplase* over placebo in normotensive patients with acute intermediate-risk PE (both treatment arms receive standard heparin anticoagulation)

Secondary To assess the safety of tenecteplase* in patients with intermediate-risk PE

PEITHO: Objectives

* Tenecteplase is not approved medication for use in pulmonary embolism in the United States or Europe.

Page 4: Pulmonary Embolism Thrombolysis Studyclinicaltrialresults.org/Slides/ACC 2013/Konstantinides_PEITHO_ACC... · Pulmonary Embolism Thrombolysis Study an investigator-initiated, investigator-sponsored

• All-cause mortality or • Hemodynamic collapse within 7 days of randomization, defined as: need for cardiopulmonary resuscitation or systolic BP < 90 mm Hg for ≥15 min or drop by ≥ 40 mm Hg for ≥15 min with end organ hypoperfusion (cold extremities, urinary output < 30 mL/h, mental confusion) or need for catecholamines to maintain adequate organ perfusion and a systolic BP of >90 mm Hg

PEITHO: Primary outcome

Page 5: Pulmonary Embolism Thrombolysis Studyclinicaltrialresults.org/Slides/ACC 2013/Konstantinides_PEITHO_ACC... · Pulmonary Embolism Thrombolysis Study an investigator-initiated, investigator-sponsored

Secondary end points: • All-cause mortality within 7 days of randomization • Hemodynamic collapse within 7 days of randomization • Confirmed symptomatic pulmonary embolism recurrence within 7 days • All-cause mortality within 30 days of randomization

Safety endpoints • Non-intracranial major bleeding within 7 days • Total strokes (intracranial hemorrhage or ischemic stroke) within 7 days • Serious adverse events (SAE) within 30 days

PEITHO: Secondary efficacy and safety outcomes

All end points were adjudicated by an independent 3-member Clinical Events Committee (CEC)

Page 6: Pulmonary Embolism Thrombolysis Studyclinicaltrialresults.org/Slides/ACC 2013/Konstantinides_PEITHO_ACC... · Pulmonary Embolism Thrombolysis Study an investigator-initiated, investigator-sponsored

Day 2 Day 7 Day 30

R

DOUBLE BLIND

VKA

Sec

onra

y O

utom

es, S

AE

Prim

ary

Out

com

e, S

econ

dary

Out

com

es

Confirmed acute

symptomatic PE

Absence of hemodynamic

collapse

Confirmed RV dysfunction +

myocardial injury

UFH infusion UFH, LMWH or Fondaparinux

UFH infusion

Tenecteplase (weight-adapted bolus)

Placebo

VKA UFH bolus i.v.

<2 h

UFH, LMWH or Fondaparinux

S Konstantinides for the PEITHO Steering Committee. Am Heart J 2012;163:33-38.e1

PEITHO: Overview of study design

ClinicalTrials.gov # NCT00639743 EudraCT # 2006-005328-18

Page 7: Pulmonary Embolism Thrombolysis Studyclinicaltrialresults.org/Slides/ACC 2013/Konstantinides_PEITHO_ACC... · Pulmonary Embolism Thrombolysis Study an investigator-initiated, investigator-sponsored

PEITHO: Analyzed population

*all ITT patients received study medication

Safety population*

ITT Population

Randomized (N=1006)

Tenecteplase Placebo

The PEITHO Investigators

500

499

499 506

506

506

First Patient In: November 2007; Last Patient Out: August 2012

1 ICF unavail.

Presenter
Presentation Notes
EINSTEIN PE: patient flow This slide shows the patient flow in the EINSTEIN PE study.
Page 8: Pulmonary Embolism Thrombolysis Studyclinicaltrialresults.org/Slides/ACC 2013/Konstantinides_PEITHO_ACC... · Pulmonary Embolism Thrombolysis Study an investigator-initiated, investigator-sponsored

Tenecteplase (n=506)

Placebo (n=499)

Age (y,) mean+SD 66.5+14.7 65.8+15.9

Age (y), median (Q1-Q3) 70.0 (57.0-78.0) 70.0 (58.0-78.0)

Sex (female/male) 264/242 268/231

Weight (kg), mean+SD 82.5+17.9 82.6+18.2

Systolic blood pressure (mm Hg), mean+SD 130.8+18.3 131.3+18.5

Diastolic blood pressure (mm Hg), mean+SD 78.6+12.6 79.2+12.1

Heart rate (beats per min), mean+SD 94.5+17.1 92.3+16.7

Respiratory rate (resp per min), mean+SD 21.8+5.8 21.6+5.7

Chronic obstructive pulmonary disease (%) 26 (5.1) 34 (6.8)

Chronic heart failure (%) 21 (4.2) 26 (5.2)

Previous VTE (%) 126 (24.9) 147 (29.5)

Known malignant tumor (%) 41 (8.1) 32 (6.4)

Surgery or trauma in previous 30 days (%) 31 (6.1) 27 (5.4)

PEITHO: Baseline characteristics

Presenter
Presentation Notes
Verified against source data tables sent for the NEJM publication
Page 9: Pulmonary Embolism Thrombolysis Studyclinicaltrialresults.org/Slides/ACC 2013/Konstantinides_PEITHO_ACC... · Pulmonary Embolism Thrombolysis Study an investigator-initiated, investigator-sponsored

Tenecteplase (n=506)

Placebo (n=499)

Confirmation of PE (%)

CT scan 480 (94.9) 472 (94.6)

High-probability lung scan 31 (6.1) 35 (7.0)

Pulmonary angiography 6 (1.2) 8 (1.6)

At least one of the above 506 (100) 499 (100)

Confirmation of RV dysfunction

Echocardiography

Echocardiography + Spiral CT

278 (54.9)

154 (30.4)

255 (51.1)

172 (34.5) Spiral CT 74 (14.6) 72 (14.4)

At least one of the above 506 (100) 499 (100)

Confirmation of myocardial injury

Troponin I or T elevated 505 (99.8) 499 (100)

PEITHO: Diagnostic and risk stratification tests

Presenter
Presentation Notes
Verified against source data tables sent for the NEJM publication
Page 10: Pulmonary Embolism Thrombolysis Studyclinicaltrialresults.org/Slides/ACC 2013/Konstantinides_PEITHO_ACC... · Pulmonary Embolism Thrombolysis Study an investigator-initiated, investigator-sponsored

PEITHO outcomes

Page 11: Pulmonary Embolism Thrombolysis Studyclinicaltrialresults.org/Slides/ACC 2013/Konstantinides_PEITHO_ACC... · Pulmonary Embolism Thrombolysis Study an investigator-initiated, investigator-sponsored

Tenecteplase (n=506)

Placebo (n=499) P value

n (%) n (%)

All-cause mortality or hemodynamic collapse within 7 days of randomization

13 (2.6) 28 (5.6) 0.015

ITT population The PEITHO Investigators

PEITHO: Primary efficacy outcome

1.00 0

0.23 0.44

2.00 Odds ratio

Thrombolysis superior

0.88

Presenter
Presentation Notes
Verified against source data tables sent for the NEJM publication
Page 12: Pulmonary Embolism Thrombolysis Studyclinicaltrialresults.org/Slides/ACC 2013/Konstantinides_PEITHO_ACC... · Pulmonary Embolism Thrombolysis Study an investigator-initiated, investigator-sponsored

Tenecteplase (n=506)

Placebo (n=499) P value

n (%) n (%) All-cause mortality within 7 days

6 (1.2) 9 (1.8) 0.43

Hemodynamic collapse within 7 days

8 (1.6) 25 (5.0) 0.002

Need for CPR 1 5

Hypotension / blood pressure drop

8 18

Catecholamines 3 14

Resulted in death 1 6

ITT population The PEITHO Investigators

PEITHO: Analysis of primary efficacy outcome

Presenter
Presentation Notes
Verified against source data tables sent for the NEJM publication
Page 13: Pulmonary Embolism Thrombolysis Studyclinicaltrialresults.org/Slides/ACC 2013/Konstantinides_PEITHO_ACC... · Pulmonary Embolism Thrombolysis Study an investigator-initiated, investigator-sponsored

Tenecteplase (n=506)

Placebo (n=499) P value

n (%) n (%) PE recurrence 1 (0.2) 5 (1.0) 0.12

Intubation / mechanical ventilation

8 (1.6) 15 (3.0) 0.13

Open-label thrombolysis 4 (0.8) 23 (4.6) <0.001

ITT population The PEITHO Investigators

PEITHO: Other clinical outcomes (within 7 days)

Presenter
Presentation Notes
Verified against source data tables sent for the NEJM publication
Page 14: Pulmonary Embolism Thrombolysis Studyclinicaltrialresults.org/Slides/ACC 2013/Konstantinides_PEITHO_ACC... · Pulmonary Embolism Thrombolysis Study an investigator-initiated, investigator-sponsored

Tenecteplase (n=506)

Placebo (n=499) P value

n (%) n (%) Non-intracranial bleeding

Major 32 (6.3) 6 (1.5) <0.001 Minor 165 (32.6) 43 (8.6) <0.001

ISTH major bleeding 58 (11.5) 12 (2.4) <0.001

Type of bleeding

Fatal 1 0

Intracranial/hemorrhagic stroke 10 1

Extracranial major 4 1

Hemoglobin drop >2g/dL 46 11

Transfusion of >2 units 10 0

ITT population The PEITHO Investigators

PEITHO: Safety outcomes (within 7 days of randomization)

Presenter
Presentation Notes
Verified against source data tables sent for the NEJM publication
Page 15: Pulmonary Embolism Thrombolysis Studyclinicaltrialresults.org/Slides/ACC 2013/Konstantinides_PEITHO_ACC... · Pulmonary Embolism Thrombolysis Study an investigator-initiated, investigator-sponsored

Tenecteplase (n=506)

Placebo (n=499) P value

n (%) n (%) All strokes by day 7 12 (2.4) 1 (0.2) 0.003

Hemorrhagic 10 1 Ischemic 2 0

Serious adverse events (SAE) 29 (5.7) 39 (7.8) 0.19

ITT population The PEITHO Investigators

PEITHO: Safety outcomes (2)

Presenter
Presentation Notes
Verified against source data tables sent for the NEJM publication
Page 16: Pulmonary Embolism Thrombolysis Studyclinicaltrialresults.org/Slides/ACC 2013/Konstantinides_PEITHO_ACC... · Pulmonary Embolism Thrombolysis Study an investigator-initiated, investigator-sponsored

Tenecteplase (n=506)

Placebo (n=499) P value

n (%) n (%) All-cause mortality 12 (2.4) 16 (3.2) 0.42

From hemodynamic collapse 1 3 From recurrent PE 1 3 From respiratory failure 0 3

From stroke 5 1

From bleeding 2 0

Other cause 3 6

ITT population The PEITHO Investigators

PEITHO: Causes of death (within 30 days of randomization)

Presenter
Presentation Notes
Verified against source data tables sent for the NEJM publication
Page 17: Pulmonary Embolism Thrombolysis Studyclinicaltrialresults.org/Slides/ACC 2013/Konstantinides_PEITHO_ACC... · Pulmonary Embolism Thrombolysis Study an investigator-initiated, investigator-sponsored

1.00 0

0.12 0.33

2.00 Odds ratio

0.85

1.00 0

0.23 0.63

2.00 Odds ratio

1.66

PEITHO: Primary end point according to age

Age ≤ 75 years

Age >75 years

ITT population The PEITHO Investigators

Page 18: Pulmonary Embolism Thrombolysis Studyclinicaltrialresults.org/Slides/ACC 2013/Konstantinides_PEITHO_ACC... · Pulmonary Embolism Thrombolysis Study an investigator-initiated, investigator-sponsored

ITT population The PEITHO Investigators

%

≤ 75 years >75 years

N 335 344 164 162

Death or hemodynamic collapse (primary EP)

Stroke without primary EP (not leading to death or hemodynamic collapse)

PEITHO: Efficacy versus safety according to age

placebo placebo TNK TNK

Presenter
Presentation Notes
Verified against source data tables sent for the NEJM publication
Page 19: Pulmonary Embolism Thrombolysis Studyclinicaltrialresults.org/Slides/ACC 2013/Konstantinides_PEITHO_ACC... · Pulmonary Embolism Thrombolysis Study an investigator-initiated, investigator-sponsored

PEITHO: Conclusions

In patients with intermediate-risk pulmonary embolism, intravenous bolus tenecteplase significantly reduced the primary end point of death or hemodynamic collapse within 7 days of randomization.

The results of PEITHO justify the concept of risk stratification of normotensive patients with acute PE.

They confirm the notion that early “advanced” (recanalization) treatment prevents clinical deterioration in patients with evidence of right ventricular dysfunction and myocardial injury.

In PEITHO, the benefits of thrombolysis came at the cost of a significantly increased risk of major, particularly intracranial, hemorrhage.

The patient’s age should be taken into account when weighing the expected benefits versus risks of systemic thrombolysis in clinical practice.

Page 20: Pulmonary Embolism Thrombolysis Studyclinicaltrialresults.org/Slides/ACC 2013/Konstantinides_PEITHO_ACC... · Pulmonary Embolism Thrombolysis Study an investigator-initiated, investigator-sponsored

PEITHO: Organization

• Irene M. Lang Austria • Franck Verschuren Belgium • Hélène Bouvaist France • Thierry Danays (non-voting) France • Nicolas Meneveau France • Gerard Pacouret France • Mustapha Sebbane France • Jan Beyer-Westendorf Germany • Claudia Dellas Germany • Klaus Empen Germany • Annette Geibel Germany • Christian Kupatt Germany • Sebastian Schellong Germany • Holger Thiele Germany • Benjamin Brenner Israel

• Giancarlo Agnelli Italy • Cecilia Becattini Italy • Nazzareno Galiè Italy • Matteo Rugolotto Italy • Aldo Salvi Italy • Piotr Pruszczyk Poland • Adam Torbicki Poland • Ana Franca Portugal • Antoniu Petris Romania • Gabriel Tatu-Chitoiu Romania • Branislav Stefanovic Serbia • Matija Kozak Slovenia • David Jiménez Castro Spain • Nils Kucher Switzerland • Samuel Z. Goldhaber United States

Co-Chairmen (Principal Investigators) • Stavros Konstantinides, Germany/Greece • Guy Meyer, France

Trial Statistician • Eric Vicaut, France

Data Safety Monitoring Board • Thomas Meinertz, Germany (Chair) • Frans van de Werf, Belgium • Arnaud Perrier, Switzerland

Critical Events Adjudication Committee • Mareike Lankeit, Germany (Chair) • Philippe Girard, France • Olivier Sanchez, France

Steering Committee Members

Sponsor’s Representative: • Philippe Gallula, France

Page 21: Pulmonary Embolism Thrombolysis Studyclinicaltrialresults.org/Slides/ACC 2013/Konstantinides_PEITHO_ACC... · Pulmonary Embolism Thrombolysis Study an investigator-initiated, investigator-sponsored

Carl C. Kaulfersch Austria Alexandre Ghuysen Belgium Serge Motte Belgium Bernard Charbonnier France Francis Couturaud France Emile Ferrari France Jose Roul Gerald France Martial Hamon France Xavier Jacob France Khalifé Khalifé France Marcel Laurent France Christine Lorut France Florence Parent France Jeannot Schmidt France Jacques Pierre Schwob France Gabriel Steg France Bernard Tardy France Mathias M. Borst Germany Leonhard Bruch Germany Christine Espinola-Klein Germany Dirk Habedank Germany Andreas Hartmann Germany Uwe Janssens Germany Volkhard Kurowski Germany F. Joachim Meyer Germany Christian Opitz Germany

Michael Kapeliovich Israel Iolanda Enea Italy Maria Grazia Modena Italy Leonardo Goffredo Pancaldi Italy Giuseppe di Pasquale Italy Giancarlo Piovaccari Italy Vittorio Pengo Italy Rosa Maria Salvi Italy Bozena Sobkowicz Poland Jerzy Lewczuc Poland Marianna Janion Poland Jarosław D. Kasprzak Poland Targonski Ryszard Poland Lech Polonski Poland Zbigniew Gaciong Poland Tiago Judas Portugal Alexandru Cristian Nechita Romania Lucian Petrescu Romania Calin Pop Romania Mircea Vladoianu Romania Goran Koraćević Serbia Biljana Putniković Serbia Carlos Escobar Cervantes Spain Mikel Oribe Ibanez Spain Xosé Pérez Fernandez Spain María José Rodríguez Spain Christophe Wyss Switzerland

PEITHO: Investigators

PEITHO Investigators

Page 22: Pulmonary Embolism Thrombolysis Studyclinicaltrialresults.org/Slides/ACC 2013/Konstantinides_PEITHO_ACC... · Pulmonary Embolism Thrombolysis Study an investigator-initiated, investigator-sponsored

PEITHO: Acknowledgements

Special thanks to: • Laurence Guery, France • Erich Bluhmki, Germany • Gudrun Heinrichs, Germany • Anke Hallmann, Germany • Anja Kronenberg, Germany • Raoul Stahrenberg, Germany • Jeannette Veuhoff, Germany • Elena Forlanelli, Italy • Miriam Mazzoleni, Italy • Cinzia Nitti, Italy • Marco Villa, Italy • Maciej Kostrubiec, Poland

Study CRO • Pierrel Research

Page 23: Pulmonary Embolism Thrombolysis Studyclinicaltrialresults.org/Slides/ACC 2013/Konstantinides_PEITHO_ACC... · Pulmonary Embolism Thrombolysis Study an investigator-initiated, investigator-sponsored
Page 24: Pulmonary Embolism Thrombolysis Studyclinicaltrialresults.org/Slides/ACC 2013/Konstantinides_PEITHO_ACC... · Pulmonary Embolism Thrombolysis Study an investigator-initiated, investigator-sponsored

PEITHO: Inclusion criteria

1) Age ≥ 18 years 2) Acute PE confirmed by: ù

a) lung scan, or b) spiral CT, or c) pulmonary angiogram

3) RV dysfunction plus myocardial injury: a) echocardiography or CT PLUS b) positive troponin I or T test

Page 25: Pulmonary Embolism Thrombolysis Studyclinicaltrialresults.org/Slides/ACC 2013/Konstantinides_PEITHO_ACC... · Pulmonary Embolism Thrombolysis Study an investigator-initiated, investigator-sponsored

PEITHO: Key exclusion criteria

Hemodynamic collapse at presentation (high-risk PE); Known significant bleeding risk Administration of thrombolytic agents within the 4 previous days Vena cava filter insertion or pulmonary thrombectomy within the 4

previous days Known coagulation disorder (including vitamin K antagonist) Treatment with an investigational drug under another study protocol in

the 7 previous days Previous enrollment in this study Any other condition that the investigator feels would place the patient at

increased risk of the investigational therapy is initiated

Page 26: Pulmonary Embolism Thrombolysis Studyclinicaltrialresults.org/Slides/ACC 2013/Konstantinides_PEITHO_ACC... · Pulmonary Embolism Thrombolysis Study an investigator-initiated, investigator-sponsored

Weight (kg) Dose in mg Dose in units Dose in ml <60 30 mg 6000 U 6 ml >60 to <70 35 mg 7000 U 7 ml >70 to <80 40 mg 8000 U 8 ml >80 to <90 45 mg 9000 U 9 ml >90 50 mg 10000 U 10 ml

Weight-adapted bolus of TNK (or placebo)

Page 27: Pulmonary Embolism Thrombolysis Studyclinicaltrialresults.org/Slides/ACC 2013/Konstantinides_PEITHO_ACC... · Pulmonary Embolism Thrombolysis Study an investigator-initiated, investigator-sponsored

Tenecteplase (n=506)

Placebo (n=499) P value

n (%) n (%) Death by day 7 6 (1.2) 9 (1.8) 0.43

From hemodynamic collapse 1 3 From recurrent PE 0 3 From stroke 4 0

From bleeding 1 0

Other cause 0 3

ITT population The PEITHO Investigators

PEITHO: Causes of death (within 7 days of randomization)

Presenter
Presentation Notes
Verified against source data tables sent for the NEJM publication